Pharmacy, Health Sciences & Exercise Science
Eptifibatide in Acute Coronary Syndrome
Document Type
Oral Presentation
Location
Indianapolis, IN
Subject Area
Pharmacy, Health Sciences & Exercise Science
Start Date
11-4-2014 8:30 AM
End Date
11-4-2014 10:00 AM
Sponsor
Kena Lanham (Butler University)
Description
Background: Eptifibatide is a glycoprotein IIb/IIIa inhibitor indicated for use in acute coronary syndrome (ACS), including patients who are medically managed or undergo percutaneous coronary intervention (PCI). Numerous trials have demonstrated a reduction in recurrent myocardial infarction, death, and other vascular events following PCI with the use of eptifibatide. Although proven to be beneficial, eptifibatide is associated with an increased risk of bleeding, especially if the medication is not dosed properly, not utilized as indicated, or if a patient has impaired renal function.
Study Objective: To assess the use of eptifibatide in patients who received the medication at St. Vincent Hospital-Indianapolis from January 1, 2011 through December 31, 2012.
Methods: The study authors conducted a retrospective chart review to assess the dosing regimen, indication, patient renal function, and concomitant use of antithrombotics in all patients, aged 18 years or older, that received eptifibatide at St. Vincent Hospital-Indianapolis from January 1, 2011 through December 31, 2012. A list of patients who received eptifibatide was obtained from pharmacy billing records, and all collected information remained confidential and was recorded without patient-specific identifiers. Descriptive statistics were utilized to analyze the data collected.
Significance: The goal of this study was to assess the use of eptifibatide in order to ensure patient safety, promote efficient use of resources, and in general, identify any short-comings in optimizing the use of eptifibatide at St. Vincent Hospital-Indianapolis.
Eptifibatide in Acute Coronary Syndrome
Indianapolis, IN
Background: Eptifibatide is a glycoprotein IIb/IIIa inhibitor indicated for use in acute coronary syndrome (ACS), including patients who are medically managed or undergo percutaneous coronary intervention (PCI). Numerous trials have demonstrated a reduction in recurrent myocardial infarction, death, and other vascular events following PCI with the use of eptifibatide. Although proven to be beneficial, eptifibatide is associated with an increased risk of bleeding, especially if the medication is not dosed properly, not utilized as indicated, or if a patient has impaired renal function.
Study Objective: To assess the use of eptifibatide in patients who received the medication at St. Vincent Hospital-Indianapolis from January 1, 2011 through December 31, 2012.
Methods: The study authors conducted a retrospective chart review to assess the dosing regimen, indication, patient renal function, and concomitant use of antithrombotics in all patients, aged 18 years or older, that received eptifibatide at St. Vincent Hospital-Indianapolis from January 1, 2011 through December 31, 2012. A list of patients who received eptifibatide was obtained from pharmacy billing records, and all collected information remained confidential and was recorded without patient-specific identifiers. Descriptive statistics were utilized to analyze the data collected.
Significance: The goal of this study was to assess the use of eptifibatide in order to ensure patient safety, promote efficient use of resources, and in general, identify any short-comings in optimizing the use of eptifibatide at St. Vincent Hospital-Indianapolis.